Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06086132

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry

This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Related Cardiovascular Toxicity

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Bologna, Bologna, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years old or older
  • Capable of giving informed consent
  • Diagnosis of cancer scheduled for treatment according to treating physician's discretion
  • Life expectancy >1 year
  • For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs

Exclusion criteria

  • Age <18 years old
  • Not able to give informed consent
  • Life expectancy <1 year
  • Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's

Treatment and study plan

Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy

Combination Product

Follow-up visits at baseline, 3-months, and 1-year

Other names: Non-interventional patient registry

Primary outcomes

  1. All causes mortality

    Time frame: For approximately a median of 3 years

    Occurrence of all cause death

  2. Cardiovascular mortality

    Time frame: For approximately a median of 3 years

    Occurrence of cardiovascular mortality

  3. Cancer therapy-related cardiovascular toxicity

    Time frame: For approximately a median of 3 years

    Occurrence of cancer therapy-related cardiovascular toxicity

Study contacts

Contact information is provided by the study sponsor or research team.

Edina Cenko

CONTACT

[email protected]

+3905121444911

Maria Bergami

CONTACT

[email protected]

+3905121444911

Sponsors and collaborators

Lead sponsor

University of Bologna

Other

Collaborators

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Registry information

Official study title

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 17, 2023
Registry last updated
Jun 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.